[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ventricular-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ventricular-dysfunction":272},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,66,102,139,164,191,216],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100427656",false,"NCT04848844","The PAtients pResenTing With COngenital HeaRt DIseAse Register (ARTORIA-R)","The PAtients pResenTing With COngenital HeaRt DIseAse Register (ARTORIA-R): A Global Register to Investigate Factors Associated With Morbidity and Mortality in Adult Patients With Congenital Heart Disease (ACHD) on the Waiting List for Heart or Heart\u002FLung Transplantation","ARTORIA-R","Inclusion Criteria:\n\n1. The patient has to be listed as an adult transplant candidate in the country the data is obtained with an age ≥18 years\n2. The patient has to have a congenital heart defect or an inherited cardiomyopathy (specific; hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy or non-compaction cardiomyopathy) which is often included into the category ACHD\n3. Data is obtained from the first evaluation for listing or listing for heart-only or heart-combined organ transplantation\n4. Transfer of anonymised data\n5. The institution\u002Forganization agrees to the memorandum how data is managed, and scientific cooperation is planned between all institutions\n\nExclusion Criteria:\n\na. The patient is listed for a second heart transplantation (retransplantation)","ALL","18 Years",{"count":19,"type":20},2000,"ESTIMATED","30 Years","OBSERVATIONAL","Advances in surgical and medical care have led to improved outcomes in patients with congenital heart disease (CHD). As a consequence, the majority of patients nowadays survives to adulthood (adults with CHD, that is, adult CHD \\[ACHD\\]) with good quality of life. Despite the surgical success, the morbidity and mortality of ACHD is higher than in the general population and is linked to the development of heart failure (HF) in adulthood.\n\nHF occurs in approximately 25% of patients with ACHD, even in those patients in whom the congenital mal-formation has been corrected successfully in childhood. The time course and presentation are heterogeneous owing to variable congenital malformation and limitation of treatment options. ACHD with an anatomic right ventricle as the systemic ventricle (e.g., atrial switch operation in patients with transposition of the great arteries \\[TGAs\\]) and those with a functional single ventricle (e.g., Fontan circulation) appear to be at higher risk of developing HF. Young age at initial corrective surgery-often in the first 2 years of life-and lack of specific medical therapies can contribute to a high and early demand for heart transplantation in patients with ACHD.",[25,26,27,28,29],"Congenital Heart Disease","Heart Failure","Transplant; Complication, Failure","Arrythmia","Ventricular Dysfunction","RECRUITING","2026-06-28",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":36,"type":34},"2020-09-02",{"date":38,"type":20},"2030-07-30",{"name":40,"class":41},"Universitätsklinikum Hamburg-Eppendorf","OTHER",1,{"id":44,"slug":4,"hasResults":10,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100565375","NCT06641362","Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)","Pivotal Clinical Study of VDI's Ultra-High Frequency Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED): THE SYNC Study","SYNC","Inclusion Criteria:\n\n* Adults with bradycardia or heart failure scheduled for first time pacemaker implant (including CRT\u002FCSP) with one of the following: Bradycardia with ventricular synchrony and QRS duration \\\u003C= 110 ms, Bradycardia with LBBB, Bradycardia with RBBB, Bradycardia with other IVCD necessitating intervention, or Heart failure with LBBB\n* Understands the nature of the study and is willing to comply with all study requirements.\n* Provides written informed consent.\n* A negative pregnancy test prior to the procedure for participants of child-bearing potential.\n\nExclusion Criteria:\n\n* Complete AV block (3rd-degree AV block) without a stable escape rhythm or other circumstances where there is no measurable QRS.\n* Subjects with a previous or current pacemaker or defibrillator implant.\n* Anatomical or other conditions that may make a 12-lead ECG difficult to obtain, such as an allergy to components of the ECG pads, burns, open wounds, etc.\n* Currently enrolled in another investigational device or drug trial that has not completed the active treatment phase and\u002For would conflict with this study.\n* Other co-morbid condition(s) that could limit the participant's ability to participate in the study or to comply with study requirements or impact the scientific integrity of the study.",{"count":51,"type":20},360,"The purpose of this study is to demonstrate the safety and effectiveness of the VDI UHF-ECG System in the diagnosis of ventricular dyssynchrony when compared to the 12-lead ECG in patients with bradycardia and heart failure indicated for pacemaker implantation.",[54,26,29],"Bradycardia","2026-05-04",{"date":57,"type":34},"2026-05-05",{"date":59,"type":34},"2025-03-18",{"date":61,"type":20},"2027-05",{"name":63,"class":64},"VDI Technologies","INDUSTRY",12,{"id":67,"slug":4,"hasResults":10,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":73,"enrollmentInfo":74,"targetDuration":76,"studyType":22,"phases":4,"briefSummary":77,"conditions":78,"keywords":85,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":42},"100598543","NCT07072858","Using Cardiac MRI to Predict Outcomes in Patients With STEMI","Prognostic Value of Cardiac Magnetic Resonance Parameters in Patients With ST-Segment Elevation Myocardial Infarction","CMR-RISK-STEMI","Inclusion Criteria:\n\n* Age between 18 and 80 years\n\nDiagnosed with ST-segment elevation myocardial infarction (STEMI), defined as chest pain with ST-segment elevation on ECG and elevated cardiac troponin levels\n\nUnderwent primary percutaneous coronary intervention (PCI)\n\nAble to undergo cardiac magnetic resonance (CMR) imaging within 7 days post-PCI\n\nProvided written informed consent\n\nExclusion Criteria:\n\n* Contraindications to CMR (e.g., severe claustrophobia, implanted cardiac defibrillators or non-compatible pacemakers)\n\nHistory of revascularization therapy (PCI or CABG) within the previous 6 months\n\nSevere valvular heart disease or known cardiomyopathy\n\nPresence of bundle branch block or fascicular block that interferes with image interpretation\n\nKnown allergy to gadolinium-based contrast agents (for those undergoing contrast-enhanced sequences)\n\nEstimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m² (if contrast use is anticipated)\n\nPregnant or breastfeeding women","80 Years",{"count":75,"type":20},1000,"5 Years","This prospective, multicenter observational study aims to evaluate the prognostic value of a comprehensive set of cardiac magnetic resonance (CMR) imaging parameters in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The study integrates advanced artificial intelligence (AI) techniques to extract and analyze high-dimensional imaging features from multiple CMR sequences-including cine, strain mapping, and functional sequences-going beyond traditional measures such as infarct size or microvascular obstruction.\n\nThe primary objective is to identify novel prognostic markers from routinely acquired CMR images that reflect myocardial structure, function, and mechanical deformation (strain), and to assess their association with long-term clinical outcomes. In addition to standard parameters, the study includes a detailed evaluation of left and right ventricular systolic and diastolic volumes, ejection fractions, and biventricular strain components (including longitudinal, circumferential, and radial strain), as well as left and right atrial volumes, emptying fractions, and reservoir\u002Fconduit\u002Fbooster strain indices.\n\nApproximately 1000 STEMI patients will undergo CMR scanning within one week after PCI. The imaging data will be subjected to AI-based feature extraction and dimensionality reduction algorithms to uncover latent patterns associated with adverse outcomes. Patients will be followed for up to three years for the occurrence of major adverse cardiovascular events (MACE), including cardiovascular death, recurrent myocardial infarction, and heart failure hospitalization.\n\nThe central hypothesis is that comprehensive CMR functional and strain-derived parameters, when analyzed using AI-driven models, offer independent and incremental prognostic value beyond conventional clinical risk factors. This study seeks to establish a data-driven, multimodal imaging framework for personalized risk stratification in STEMI patients, potentially enabling more precise post-infarction management strategies.\n\nNo investigational treatment is involved. All imaging and clinical data are collected as part of routine care and analyzed retrospectively for outcome prediction.",[79,80,81,82,83,84,29],"Myocardial Infarction (MI)","ST Segment Elevation Myocardial Infarction (STEMI)","Magnetic Resonance Imaging (MRI)","Heart Ventricles","Artificial Intelligence (AI)","Prognosis",[86,87,88,89,90,91,92],"ST Segment Elevation Myocardial Infarction","Cardiac Magnetic Resonance Imaging","Cardiac Strain Imaging","Machine Learning","Image Analysis","Survival Analysis","Multimodal Imaging","2025-07-09",{"date":95,"type":34},"2025-07-18",{"date":97,"type":34},"2014-01-01",{"date":99,"type":20},"2025-12-30",{"name":101,"class":41},"Chinese PLA General Hospital",{"id":103,"slug":4,"hasResults":10,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":109,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":112,"conditions":113,"keywords":121,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":138},"100589079","NCT06949748","Flecainide in Idiopathic Premature Ventricular Contractions and Related Cardiomyopathy","UNIFLECA Study: Prospective Cohort Study on Flecainide's Impact on Persistent High Premature Ventricular Contraction Burden and PVC-Induced Cardiomyopathy","UNIFLECA","Inclusion Criteria:\n\n* Frequent idiopathic PVCs (burden \\>5% on multiple 24-hour Holter ECG recordings)\n* Normal cardiac structure and function on echocardiography\n* No late gadolinium enhancement or myocardial scar on cardiac MRI\n* Normal coronary angiography (excluding ischemic cardiomyopathy)\n* Normal serum electrolytes and renal function\n* Willingness to comply with follow-up schedule and drug titration\n\nExclusion Criteria:\n\n* Structural heart disease\n* Ischemic heart disease (confirmed by angiography)\n* History of sustained ventricular arrhythmias\n* Left ventricular ejection fraction (LVEF) \\\u003C40% at baseline\n* Brugada syndrome, long QT syndrome, or other channelopathies\n* Contraindications to class IC agents\n* Use of concurrent antiarrhythmics or proarrhythmic drugs",true,{"count":111,"type":20},300,"The UNIFLECA study is a prospective, single-arm, observational cohort evaluating the efficacy, safety, and tolerability of flecainide (in the form of Sanocard) in adults with frequent idiopathic premature ventricular contractions (PVCs) and suspected PVC-induced cardiomyopathy (PVCi-CMP). Frequent PVCs-defined as a burden \\>5% on two separate 24-hour Holter recordings-are increasingly recognized as a cause of reversible systolic dysfunction in patients without structural heart disease.\n\nParticipants undergo a comprehensive baseline evaluation including echocardiography, occasionally cardiac MRI, and coronary angiography or equivalent testing to confirm the absence of structural abnormalities. Patients are enrolled only if they are ineligible or unwilling to undergo catheter ablation, and have no contraindications to flecainide.\n\nFlecainide therapy is initiated at a starting dose of 100 mg\u002Fday and titrated up to 200 mg\u002Fday, guided by ECG findings, symptom response, and QRS duration. Regular follow-up occurs at three-month intervals over three years, with periodic 24-hour Holter monitoring and assessment of symptoms, LVEF, and adverse events.\n\nThe primary outcome is the reduction in PVC burden. Secondary outcomes include improvement in LVEF, symptom relief (measured by structured questionnaires), adverse effects, and long-term treatment adherence. The study aims to generate real-world data on the non-invasive management of PVCs with flecainide and explore its role as an alternative to ablation in carefully selected patients.",[114,115,116,117,118,29,119,120],"Premature Ventricular Beats","Premature Ventricular Complexes","Premature Ventricular Contraction (PVC)","Arrhythmia Ventricular","Ventricular Dysfunction, Left","Cardiomyopathies, Secondary","Cardiomyopathies",[122,123,107,124,125,126,127,128],"Flecainide","Sanocard","PVC induced CMP","PVC","Premature Ventricular Contraction","Outflow Tract PVC","NonOutflow Tract PVC","2025-06-27",{"date":131,"type":34},"2025-07-02",{"date":133,"type":34},"2024-04-26",{"date":135,"type":20},"2027-12-01",{"name":137,"class":41},"University of Athens",6,{"id":140,"slug":4,"hasResults":10,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":146,"phases":147,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":42},"100538134","NCT06286878","Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes","Inclusion Criteria:\n\n* Men and women aged ≥ 18 years (women of childbearing age must have a negative pregnancy test);\n* In routine use of dual antiplatelet therapy with ASA plus an ADP receptor antagonist, according to institutional routines;\n* Acute myocardial infarction, with or without ST-segment elevation (STEMI\u002FNSTEMI) defined according to the 4th Universal Definition of Acute Myocardial Infarction, with up to 7 days of evolution from the onset of symptoms;\n* Signature of the Free and Informed Consent Term.\n\nExclusion criteria:\n\n* Current or recent (within 24 months) treatment with pioglitazone and\u002For use of pioglitazone for a total of 2 years or more during a lifetime at any time;\n* Current or recent (within 12 months) treatment with rosiglitazone;\n* Chronic use (\\>15 consecutive days) of any SGLT2 inhibitor at the time of hospitalization;\n* Chronic use (\\>30 consecutive days) with an oral steroid at a dose equivalent to prednisolone ≥10 mg (eg, betamethasone ≥1.2 mg, dexamethasone ≥1.5 mg, hydrocortisone ≥40 mg) per day;\n* Systolic BP \\> 180 or diastolic BP \\> 100 mmHg at randomization;\n* Diagnosis of Type 1 diabetes mellitus, MODY (maturity onset diabetes of the Young) or diabetes mellitus secondary to diverse endocrinopathy, pancreatic resection, medication, pancreas neoplasia or chronic pancreatitis;\n* History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time;\n* History of any other malignancy within 5 years (with the exception of skin cancers successfully treated non-melanoma);\n* Chronic cystitis and\u002For recurrent urinary tract infections (3 or more in the last year);\n* Any condition that, in the opinion of the Investigator, may render the research participant unfit to complete the study, including, but not limited to, cardiovascular disease (KILLIP \\> 2, modified Forester \\> IIa,35 recurrent ventricular arrhythmias) or non cardiovascular (eg, active malignancy other than basal cell carcinoma, cirrhosis, chronic lung disease, severe autoimmune disease);\n* Pregnancy or lactation;\n* Active participation in another clinical trial\n* Patients with septic shock or severe glycemic decompensation requiring the use of IV insulin at the time of randomization;\n* TGP\u002FALT(Alanine Amino Transferase) \\>3x the upper limit of normality (ULN) or total bilirubin \\>2.5 x ULN;\n* Estimated glomerular filtration rate (GFR) \\\u003C 45 ml\u002Fmin\u002F1.73m² , calculated by MDRD, or kidney transplant;\n* Known thrombophilias or thrombocytosis;\n* Blood dyscrasias or any disorder that causes hemolysis, previously known;\n* Hematological abnormality (Hb ≤ 11g\u002FdL or \\> 17g\u002FdL, leukocytes ≤ 4500\u002Fmm³ or \\>11000\u002Fmm³, platelet count \\\u003C150,000\u002Fmm³ or \\> 450,000\u002Fmm³)",{"count":145,"type":20},80,"INTERVENTIONAL",[148,149],"PHASE2","PHASE3","Type 2 diabetes mellitus (T2DM) is one of the most important risk factors for atherosclerotic heart disease. Strategies focused solely on glycemic control have failed to demonstrate vascular events reduction in this population. On the other hand, new antidiabetic drugs recently have demonstrated significant decrease of cardiovascular mortality, raising the hypothesis that possible effects beyond glycemia control could explain this benefit. Aim: This study is intended to evaluate possible pleiothropic effects of dapaglifozin, a SGLT-2 (sodium glucose cotransporter 2) inhibitor, in individuals admitted with a diagnosis of Acute Myocardial Infarction (AMI). Methods: This is a prospective, randomized, double-blind, placebo controlled trial. Individuals presenting with AMI whithin the first seven days of evolution will be randomized to dapaglifozin or placebo. The investigators's goal is to analyze platelet aggregability 48 hours after randomization (primary endpoint), as well as glycemic control, cardiac biomarkers, corrected QT interval electrocardiographic analysis, autonomic modulation through spectral analysis of the RR interval and inflammatory biomarkers at inclusion and 30 days after starting study drug (secondary endpoints). Sample size calculation resulted in 80 individuals (40 per group). Expected results: This study will seek to aggregate new insights to the current knowledge about this new antidiabetic drug class. Previous randomized clinical trials have demonstrated that SGLT-2 inhibitors significantly reduced the composite endpoint of cardiovascular death, AMI or stroke, as well as Heart Failure (HF) hospitalization. Therefore, this study is supposed to clarify possible mechanisms that could explain these results aforementioned.",[152,153,154,29],"Myocardial Infarction","Acute Coronary Syndrome","Diabetes","2025-04-22",{"date":157,"type":34},"2025-04-25",{"date":159,"type":34},"2021-12-08",{"date":161,"type":20},"2025-07-30",{"name":163,"class":41},"University of Sao Paulo",{"id":165,"slug":4,"hasResults":10,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":10,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":170,"targetDuration":172,"studyType":22,"phases":4,"briefSummary":173,"conditions":174,"keywords":178,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":42},"100422546","NCT04782232","Registry to Assess the Safety and Feasibility of the Subpulmonary Support with the Novel Venous Cannula in Patients with Failing\u002FAbsence of the Right Heart","RegiVe","Inclusion Criteria:\n\n* Patient or his\u002Fher parent\u002Fguardian or legally authorized representative has given the consent by means of a written, signed and dated informed consent form,\n* The indications on RVAD and BVAD use of the EXCOR VAD apply,\n* Patient shall be on transplant list or at least eligible for HTx,\n* BSA (body surface area) greater than or equal to 1.2 m².\n\nExclusion Criteria:\n\n* Patient or his\u002Fher parents\u002Flegal guardian or legally authorized guardian has not given the consent,\n* The contraindications of EXCOR VAD apply.",{"count":171,"type":20},20,"12 Months","The purpose of the study is to monitor the clinical safety and performance of the EXCOR Venous Cannula in context of an EXCOR VAD therapy to ensure continued acceptability of identified risks, to enable detecting emerging risks and to assess clinical improvement on both short- and long-term.",[26,175,29,176,177],"Univentricular Heart","Heart Diseases","Cardiovascular Diseases",[179,180,181],"EXCOR Ventricular Assist Device","EXCOR Venous Cannula","Failing Fontan","2025-02-13",{"date":184,"type":34},"2025-02-17",{"date":186,"type":34},"2021-06-01",{"date":188,"type":20},"2027-09",{"name":190,"class":64},"Berlin Heart GmbH",{"id":192,"slug":4,"hasResults":10,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":109,"sex":197,"minAge":4,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":200,"conditions":201,"keywords":204,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":42},"100504647","NCT05851053","Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study","BLOC-II","Inclusion Criteria:\n\n* Patients who previously took part in de BLOC-I study will be included. These criteria were:\n* females diagnosed with stage I-III BC at least five years ago or local or locoregional recurrence of BC at least five years ago\n* treatment with chemotherapy and\u002For radiotherapy.\n\nExclusion Criteria:\n\n* Patients unfit to travel to the hospital due to severe mental or physical illness, based on assessment by their GP.\n\nExclusion criteria for the BC survivors in the BLOC-I study were:\n\n* metastatic disease at the time of BC diagnosis;\n* BC treatment after 80 years of age;\n* history of treatment for other types of cancer.","FEMALE",{"count":199,"type":20},455,"Rationale: In addition to surgery, effective breast cancer (BC) treatment typically requires chemotherapy, radiotherapy, or both. However, it is still unclear whether patients with BC are at increased risk of long-term cardiac dysfunction due to the adverse effects of these therapies. In a cross-sectional study in primary care, a comparison on cardiac dysfunction between 350 BC survivors and 350 age- and general practitioner (GP)- matched controls without cancer was made. In that study, BC survivors were at increased risk of mild systolic cardiac dysfunction (left ventricle ejection fraction (LVEF)\\\u003C 54%). By contrast, there was no significant difference in an LVEF \\\u003C 50% or in diastolic dysfunction. To date it remains uncertain whether the mild or subclinical dysfunction we observed predicts further cardiac deterioration. Consequently, the translation of these results into guidelines for the daily practice of the GP is unclear.\n\nObjective: The aim of the here proposed study is to clarify whether cardiac function in survivors of BC should be monitored by GPs, by assessing whether an unselected population of long-term BC survivors is at increased risk of developing cardiac dysfunction, whether in this group at-risk subgroups exists, and what factors are associated with the highest risk.\n\nStudy design: A new assessment of cardiac function among women included in the BLOC-I study. This produces a longitudinal matched cohort design consisting of two cohorts in primary care.\n\nStudy population: Survivors of BC, diagnosed ≥11 years ago who received chemotherapy and\u002For radiotherapy, and a matched reference population with no history of cancer. All participants participated in the Breast cancer Long-term Outcome of Cardiac function (BLOC-I) study.\n\nMain study parameters\u002Fendpoints: Left ventricular systolic dysfunction. Systolic cardiac dysfunction is defined as a LVEF \\\u003C54\u002F50\u002F45%.",[202,26,203,29],"Neoplasm, Breast","Cardiotoxicity",[205,203,206],"Breast cancer","Heart failure","2024-05-28",{"date":209,"type":34},"2024-05-29",{"date":211,"type":34},"2022-09-01",{"date":213,"type":20},"2026-12-31",{"name":215,"class":41},"University Medical Center Groningen",{"id":217,"slug":4,"hasResults":10,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":225,"conditions":226,"keywords":251,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":271},"100541040","NCT06324682","ConTempoRary Cardiac Stimulation in Clinical practicE: lEft, BivEntriculAr, Right, and conDuction System Pacing","Evaluation of conTempoRary Cardiac Stimulation in Clinical practicE: lEft, BivEntriculAr, Right, and conDuction System Pacing","TREEBEARD","Inclusion Criteria:\n\n* Indication for cardiac stimulation\n* Having performed the implantation of a device for cardiac stimulation\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years;\n* Pregnancy status;",{"count":224,"type":20},8400,"The goal of this observational study is to evaluate the clinical characteristics of patients undergoing permanent cardiac pacing and to compare procedural efficacy and safety of different implantation approaches in the clinical practice of the participating centres. The contribution of non-fluoroscopic anatomical and electrophysiological reconstruction systems to device implantation procedures will also be evaluated.\n\nParticipants \\[patients over 18 years old with an indication to receive a definitive pacemaker\u002Fintracardiac defibrillator implant\\] will receive a permanent cardiac pacing implant as requested according to European Society of Cardiology (ESC) guidelines; the investigators will evaluate procedural efficacy and safety of different implantation approaches.",[227,228,229,230,231,232,29,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250],"Arrhythmias, Cardiac","Atrioventricular Block","Reduced Systolic Function","Atrial Fibrillation","Bradyarrhythmia","Ventricular Tachycardia","Ventricular Fibrillation","Ventricular Arrythmia","Atrioventricular Nodal Disease","Atrioventricular Conduction Defects","Atrioventricular Block Complete","Atrioventricular Block Incomplete","Atrioventricular Junctional Rhythm","Bundle-Branch Block","Left Bundle-Branch Block","Heart Failure, Systolic","Block;Atrioventricular","Block; Arrhythmic","Block; Mobitz","Block, Heart","Block, Fascicular","Block Branch Bundle Left","Heart Failure，Congestive","Heart Arrhythmia",[252,253,228,231,29,254,255,256,257,258,259,260,261,237,206,234,233,232],"Pace maker (PM)","Implantable cardioverter defibrillator (ICD)","Cardiac Resynchronization therapy","Conduction System Pacing","His Pacing","Left bundle branch area pacing (LBBAP)","CRT","CSP","Primary prevention","Secondary prevention","2024-03-19",{"date":264,"type":34},"2024-03-22",{"date":266,"type":34},"2023-01-01",{"date":268,"type":20},"2034-12-31",{"name":270,"class":41},"University Hospital of Ferrara",31,""]